These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 7648765)

  • 41. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects.
    Zhang YA; Reviriego J; Lou YQ; Sjöqvist F; Bertilsson L
    Clin Pharmacol Ther; 1990 Nov; 48(5):496-502. PubMed ID: 2225709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
    Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
    Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
    Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CYP2C19 polymorphism and proton pump inhibitors.
    Klotz U; Schwab M; Treiber G
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
    Kodaira C; Uchida S; Yamade M; Nishino M; Ikuma M; Namiki N; Sugimoto M; Watanabe H; Hishida A; Furuta T
    J Clin Pharmacol; 2012 Mar; 52(3):432-9. PubMed ID: 21415279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
    Caraco Y; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
    Fujisaki H; Oketani K; Shibata H; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Takeguchi N
    Nihon Yakurigaku Zasshi; 1993 Dec; 102(6):389-97. PubMed ID: 8282270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
    Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
    J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
    Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Ishizaki T
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1195-202. PubMed ID: 1527724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
    Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.